Keywords: treatment, alkermes/j, risperdal, consta, may, economic, benefits
Treatment with Alkermes/J&J's Risperdal Consta may have economic benefits
Article | 22 December 2003
Results of a study conducted in Sweden suggest that treatment ofschizophrenia patients with Alkermes/Johnson & Johnson's Risperdal Consta, a long-acting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
